Significance of COX-2 expression in human renal cell carcinoma cell lines

International Journal of Cancer

Volumn 108, Issue 6, 2004, Pages 825-832

  Chen, Qinzhong ^a   Shinohara, Nobuo ^a   Abe, Takashige ^a   Watanabe, Takafumi ^a   Nonomura, Katsuya ^a   Koyanagi, Tomohiko ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisense DNA; COX 2 inhibitor; Cyclooxygenase 2; Renal cell carcinoma; Tumorigenesis

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; NUDE MOUSE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BUTYRATES; CARCINOMA, RENAL CELL; CELL DIVISION; CELL LINE, TUMOR; CELL SEPARATION; COLORING AGENTS; CYCLOOXYGENASE 2; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; ISOENZYMES; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NITROBENZENES; OLIGONUCLEOTIDES, ANTISENSE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANSFECTION;

EID: 1642457338     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11646     Document Type: Article

References (50)

1. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-36.
2. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
3. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-3.
4. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
5. DeWitt D, Smith WL. Yes, but do they still get headaches? Cell 1995;83:345-8.
6. Elder DJ, Baker JA, Banu NA, Moorghen M, Paraskeva C. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 2002;198:428-34.
7. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 2003;9:1421-6.
8. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-71.
9. Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett SM. Abnormal interleukin 10Rα expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res 2003;63:766-70.
10. Kase S, Osaki M, Honjo S, Adachi H, Tsujitani S, Kaibara N, Ito H. Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch 2003;442:129-35.
11. Kawamoto T, Shoda J, Asano T, Ueda T, Furukawa M, Koike N, Tanaka N, Todoroki T, Miwa M. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 2002;98:427-34.
12. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
13. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ and levels of prostaglandin E2 and 15-deoxy-δ12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003:103:84-90.
14. Ranelletti FO, Almadori G, Rocca B, Ferrandina G, Ciabattoni G, Habib A, Galli J, Maggiano N, Gessi M, Lauriola L. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 2001;95:343-9.
15. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001;158:849-53.
16. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ Jr, DuBois RN, Beauchamp RD. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997;113:1883-91.
17. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000;275:6628-35.
18. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001;84:335-9.
19. Wikstrom K, Ohd JF, Sjolander A. Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2. Biochem Biophys Res Commun 2003;302:330-5.
20. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, Baba S. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59:615-20.
21. Fujita J, Kraus MH, Onoue H, Srivastava SK, Ebi Y, Kitamura Y, Rhim JS. Activated H-ras oncogenes in human kidney tumors. Cancer Res 1988;48:5251-5.
22. Khan KN, Stanfield KM, Trajkovic D, Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 2001;38:116-9.
23. Hara S, Kondo Y, Matsuzawa I, Hashimoto Y, Kimura G, Akimoto M, Imura N. Expression of cycloxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol 2002;507:123-6.
24. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9:1741-9.
25. Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. Int J Cancer 2001;92:712-7.
26. Shinohara N, Ogiso Y, Tanaka M, Sazawa A, Harabayashi T, Koyanagi T. The significance of Ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines. J Urol 1997;158:908-11.
27. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991:324:1-8.
28. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
29. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997:94:3336-40.
30. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
31. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-20.
32. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002:62:6323-8.
33. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-54.
34. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 1994;269:11769-75.
35. Okamoto T, Hara A, Hino O. Down-regulation of cyclooxygenase-2 expression but up-regulation of cyclooxygenase-1 in renal carcinomas of the Eker (TSC2 gene mutant) rat model. Cancer Sci 2003;94:22-5.
36. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
37. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127:411-7.
38. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9.
39. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72.
40. Ahnen DJ. Colon cancer prevention by NSAID: what is the mechanism of action? Eur J Surg Suppl 1998;582:111-4.
41. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-92.
42. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, Dienes HP, Breuhahn K, Schirmacher P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-94.
43. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
44. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
45. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. J Med Chem 1993;36:1923-37.
46. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992;32:329-76.
47. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.
48. Crew TE, Elder DJ, Paraskeva C. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 2000:21:69-77.
49. Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002;198:435-41.
50. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003:197:221-32.